WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
St. John's Chris Ledlum and Jordan Dingle suing NCAA for denying them 2024Maple Leafs star Auston Matthews out for potential elimination matchup with BruinsEric Church DOUBLES DOWN on Stagecoach gospel headlining setEli Lilly, 3M rise; MicroStrategy, Chegg fall, Tuesday, 4/30/2024Brad Stevens selected as NBA's executive of the year after Celtics' NBATimberwolves coach Chris Finch to have surgery on knee after sideline collision, AP source saysHoda Kotb pokes fun at Today coHouse Republicans launch investigation into federal funding for universities amid campus protestsEric Church DOUBLES DOWN on Stagecoach gospel headlining setTwins bring closer Jhoan Duran back from injured list with strained oblique muscle